Literature DB >> 28206678

Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short- and long-term risks of colectomy in inflammatory bowel disease.

C C Y Law1, R Tariq2, S Khanna2, S Murthy1, J D McCurdy1.   

Abstract

BACKGROUND: Clostridium difficile infection (CDI) is associated with increased mortality in inflammatory bowel disease (IBD), but the risk of colectomy is variable and has not been adequately studied. AIM: To perform a systematic review and meta-analysis to assess the impact of CDI on colectomy risk in IBD.
METHODS: Multiple databases were searched systematically for observational studies reporting colectomy risk in IBD, stratified by the presence of CDI, and the duration of follow-up (short term 3 months, and long term at least 1 year). Weighted summary estimates were calculated using generalised inverse variance with random-effects model. Study quality was assessed using the Newcastle-Ottawa scale.
RESULTS: Twelve observational studies were identified and included 35 057 IBD patients with CDI, and 929 259 without CDI. CDI did not increase the short-term colectomy risk in IBD patients overall (10 studies) (OR: 1.35; 95% CI: 0.68-2.67), or in patients with ulcerative colitis (nine studies) (OR: 1.20; 95% CI: 0.39-3.76). In contrast, CDI was associated with higher long-term colectomy risk in patients with IBD overall (five studies) (OR: 2.23; 95% CI: 1.18-4.21), and in patients with ulcerative colitis (four studies) (OR: 2.96; 95% CI: 1.19-7.34). The results were stable in subgroups stratified by recruitment period, hospitalisation status and geographical location. All studies were at least of moderate quality. The results were limited in the ability to compare IBD severity and the type of anti-microbial therapy.
CONCLUSION: Based on 12 observational studies with at least moderate quality, Clostridium difficile infection appears to increase colectomy risk in IBD in the long- but not short- term.
© 2017 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28206678     DOI: 10.1111/apt.13972

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

Review 1.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 2.  Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks?

Authors:  Walter Fries; Maria Giulia Demarzo; Giuseppe Navarra; Anna Viola
Journal:  Drugs Aging       Date:  2022-06-01       Impact factor: 4.271

3.  Microbial Shifts and Shorter Time to Bowel Resection Surgery Associated with C. difficile in Pediatric Crohn's Disease.

Authors:  Jennifer Hellmann; Heidi Andersen; Lin Fei; Aaron Linn; Ramona Bezold; Kathleen Lake; Kimberly Jackson; Danielle Meyer; Kelsie Dirksing; Erin Bonkowski; Nicholas J Ollberding; David B Haslam; Lee Denson
Journal:  Inflamm Bowel Dis       Date:  2020-07-17       Impact factor: 7.290

Review 4.  Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease.

Authors:  Rahul S Dalal; Jessica R Allegretti
Journal:  Curr Opin Gastroenterol       Date:  2021-07-01       Impact factor: 2.741

5.  Gut Microbiota and Metabolite Changes in Patients With Ulcerative Colitis and Clostridioides difficile Infection.

Authors:  Jian Wan; Yujie Zhang; Wenfang He; Zuhong Tian; Junchao Lin; Zhenzhen Liu; Yani Li; Min Chen; Shuang Han; Jie Liang; Yongquan Shi; Xuan Wang; Lei Zhou; Ying Cao; Jiayun Liu; Kaichun Wu
Journal:  Front Microbiol       Date:  2022-05-27       Impact factor: 6.064

Review 6.  Risk Factors, Diagnosis, and Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Livio Enrico Del Vecchio; Marcello Fiorani; Ege Tohumcu; Stefano Bibbò; Serena Porcari; Maria Cristina Mele; Marco Pizzoferrato; Antonio Gasbarrini; Giovanni Cammarota; Gianluca Ianiro
Journal:  Microorganisms       Date:  2022-06-29

7.  Clostridium difficile infection in hospitalized patients with inflammatory bowel disease: Prevalence, risk factors, and prognosis.

Authors:  Nitsan Maharshak; Idan Barzilay; Hasya Zinger; Keren Hod; Iris Dotan
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

8.  Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab.

Authors:  Elena De Cristofaro; Silvia Salvatori; Irene Marafini; Francesca Zorzi; Norma Alfieri; Martina Musumeci; Emma Calabrese; Giovanni Monteleone
Journal:  J Clin Med       Date:  2022-03-18       Impact factor: 4.241

Review 9.  Management of Clostridioides difficile infection in patients with inflammatory bowel disease.

Authors:  Sahil Khanna
Journal:  Intest Res       Date:  2020-08-18

10.  Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis.

Authors:  Shin Ju Oh; Ga Young Shin; Hosim Soh; Jae Gon Lee; Jong Pil Im; Chang Soo Eun; Kang-Moon Lee; Dong Il Park; Dong Soo Han; Hyo Jong Kim; Chang Kyun Lee
Journal:  Intest Res       Date:  2020-08-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.